Over the past 20 years, treatment of NSCLC has evolved from the empiric use of cytotoxic therapies to effective and better-tolerated regimens that are targeted to specific molecular subtypes (Epidermal growth factor receptor (EGFR), programmed death-ligand 1 (PD-L1), MET, etc.)[3]. Here, EGFR is linked to non-small cell lung carcinoma.